Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as ...

Leela Barham uses the very latest data – running up to November 2023 – to take stock of NICE’s Single Technology Appraisal (STA) recommendations on orphan drugs versus non-orphans.

Chemists at ETH Zurich have developed a new computer process that enables the generation of active pharmaceutical ingredients at speed, based on a protein’s three-dimensional surface. The new ...

Psychedelic therapies have emerged as a promising frontier in mental health treatment, sparking interest from researchers and investors alike. However, Ben Hargreaves finds the FDA rejection of ...

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then immediately hatched a plan to replace it with a late-stage candidate for metabolic dysfunction-associated steatohepatitis ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

What trends did delegates notice, in terms of new modalities, technologies, and approaches? Precision, personalisation, and ...

Summit Pharma has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to ...

The deal with Evopoint boosts Astellas' claudin pipeline as other CLDN18.2 candidates come through the industry pipeline from ...

Roche has revealed new results from a phase 2 trial of its oral BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS) that suggest it can prevent progression of the disease for nearly two ...

Philippe Masset has been appointed to the Board of Directors at Vect-Horus, a French biotech developing vectors for targeting ...

Op den Kelder grew up in the Netherlands and received his Bachelor’s degree in International Management from Fontys ...